HC Wainwright Reiterates Buy Rating for TScan Therapeutics (NASDAQ:TCRX)

TScan Therapeutics (NASDAQ:TCRX - Get Free Report)'s stock had its "buy" rating reaffirmed by equities researchers at HC Wainwright in a research report issued to clients and investors on Wednesday,Benzinga reports. They currently have a $15.00 target price on the stock. HC Wainwright's price objective points to a potential upside of 387.01% from the stock's previous close.

A number of other analysts also recently weighed in on TCRX. Needham & Company LLC restated a "buy" rating and issued a $11.00 price objective on shares of TScan Therapeutics in a report on Tuesday, November 12th. Wedbush reissued an "outperform" rating and issued a $7.00 price target (down previously from $10.00) on shares of TScan Therapeutics in a research note on Tuesday.

TScan Therapeutics Price Performance

Shares of TCRX traded down $0.25 during mid-day trading on Wednesday, reaching $3.08. The company had a trading volume of 2,182,684 shares, compared to its average volume of 259,768. The company's 50 day simple moving average is $4.96 and its 200 day simple moving average is $5.95. The company has a market capitalization of $164.38 million, a price-to-earnings ratio of -2.81 and a beta of 0.79. TScan Therapeutics has a 1-year low of $2.60 and a 1-year high of $9.69. The company has a debt-to-equity ratio of 0.13, a quick ratio of 9.56 and a current ratio of 9.56.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported ($0.25) earnings per share for the quarter, topping analysts' consensus estimates of ($0.28) by $0.03. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. The firm had revenue of $1.05 million for the quarter, compared to analysts' expectations of $2.86 million. Analysts expect that TScan Therapeutics will post -1.12 EPS for the current year.

Insider Activity

In other news, Director Barbara Klencke acquired 5,000 shares of TScan Therapeutics stock in a transaction on Monday, September 23rd. The stock was purchased at an average price of $5.29 per share, with a total value of $26,450.00. Following the completion of the purchase, the director now owns 45,000 shares of the company's stock, valued at approximately $238,050. The trade was a 12.50 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 2.76% of the stock is currently owned by company insiders.

Institutional Trading of TScan Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of TCRX. Great Point Partners LLC purchased a new stake in shares of TScan Therapeutics in the second quarter worth approximately $5,504,000. Checkpoint Capital L.P. bought a new stake in TScan Therapeutics during the third quarter worth $4,110,000. State Street Corp raised its position in TScan Therapeutics by 24.4% in the 3rd quarter. State Street Corp now owns 756,499 shares of the company's stock valued at $3,767,000 after buying an additional 148,414 shares during the last quarter. Bank of Montreal Can bought a new position in TScan Therapeutics during the 2nd quarter valued at $749,000. Finally, Bank of New York Mellon Corp purchased a new position in TScan Therapeutics during the 2nd quarter worth $682,000. Institutional investors own 82.83% of the company's stock.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.